BACKGROUND: To report feasibility, tolerance, anatomical topography of locoregional recurrence (LRR), and long-term outcome for esophageal and esophagogastric (EG) cancer patients treated with preoperative chemoradiation (CRT) and surgery with or without a radiation boost of intraoperative electron beam radiotherapy (IOERT). METHODS: From January 1995 to December 2010, 53 patients with primary esophageal (n = 26; 44 %) or EG carcinoma (n = 30; 56 %), and disease confined to locoregional area [clinical stage: IIb (n = 30; 57 %), IIIa (n = 14; 26 %), IIIb (n = 6; 11 %), IIIc (n = 3; 6 %)], were treated with preoperative CRT, curative (R0) resection with an extended (two-field) lymph node dissection in all cases. Thirty-seven patients also received a preanastomotic reconstruction IOERT boost (applicator diameter size 6-9 cm, dose 10-15 Gy, beam energy 6-15 MeV) over the tumor bed in the mediastinum and upper abdominal lymph node area. RESULTS: With a median follow-up time of 27.9 months (range, 0.2-148), LRR rate was 15 % (n = 8). Five-year overall survival (OS) and disease-free survival was 48 and 36 %, respectively. Univariate log-rank analyses showed that receiving IOERT was associated with lower risk of LRR (p = 0.004). On multivariate analysis, only the IOERT group retained significance in relation to LRR (odds ratio, 0.08; 95 % confidence interval, 0.01-0.48; p = 0.01). Postoperative mortality and perioperative complications were 11 % (n = 6) and 30 % (n = 16). CONCLUSIONS: Local control is high in the radiation-boosted area, but OS remains modest, given the high risk of distant metastases. Intensified locoregional treatment needs to be tested in the context of more efficient concurrent, neo-, and adjuvant systemic therapy.
BACKGROUND: To report feasibility, tolerance, anatomical topography of locoregional recurrence (LRR), and long-term outcome for esophageal and esophagogastric (EG) cancerpatients treated with preoperative chemoradiation (CRT) and surgery with or without a radiation boost of intraoperative electron beam radiotherapy (IOERT). METHODS: From January 1995 to December 2010, 53 patients with primary esophageal (n = 26; 44 %) or EG carcinoma (n = 30; 56 %), and disease confined to locoregional area [clinical stage: IIb (n = 30; 57 %), IIIa (n = 14; 26 %), IIIb (n = 6; 11 %), IIIc (n = 3; 6 %)], were treated with preoperative CRT, curative (R0) resection with an extended (two-field) lymph node dissection in all cases. Thirty-seven patients also received a preanastomotic reconstruction IOERT boost (applicator diameter size 6-9 cm, dose 10-15 Gy, beam energy 6-15 MeV) over the tumor bed in the mediastinum and upper abdominal lymph node area. RESULTS: With a median follow-up time of 27.9 months (range, 0.2-148), LRR rate was 15 % (n = 8). Five-year overall survival (OS) and disease-free survival was 48 and 36 %, respectively. Univariate log-rank analyses showed that receiving IOERT was associated with lower risk of LRR (p = 0.004). On multivariate analysis, only the IOERT group retained significance in relation to LRR (odds ratio, 0.08; 95 % confidence interval, 0.01-0.48; p = 0.01). Postoperative mortality and perioperative complications were 11 % (n = 6) and 30 % (n = 16). CONCLUSIONS: Local control is high in the radiation-boosted area, but OS remains modest, given the high risk of distant metastases. Intensified locoregional treatment needs to be tested in the context of more efficient concurrent, neo-, and adjuvant systemic therapy.
Authors: Felipe A Calvo; Morena Sallabanda; Claudio V Sole; Carmen Gonzalez; Laura Alonso Murillo; Javier Martinez-Villanueva; Juan A Santos; Javier Serrano; Ana Alavrez; Jose Blanco; Ana Calin; Marina Gomez-Espi; Miguel Lozano; Rafael Herranz Journal: Rep Pract Oncol Radiother Date: 2013-08-13
Authors: Felipe A Calvo; Claudio V Sole; Hugo Marsiglia; Eduardo Alvarado; Carlos Ferrer; Brian Czito Journal: Curr Oncol Rep Date: 2015-01 Impact factor: 5.075
Authors: F A Calvo; C V Sole; M E González; E D Tangco; J López-Tarjuelo; I Koubychine; J A Santos; J Pascau; R Herranz; C Ferrer Journal: Clin Transl Oncol Date: 2013-03-05 Impact factor: 3.405
Authors: Claudio V Sole; Felipe A Calvo; Carlos Ferrer; Javier Pascau; Hugo Marsiglia Journal: Strahlenther Onkol Date: 2014-06-14 Impact factor: 3.621
Authors: Felipe Ángel Calvo Manuel; Javier Serrano; Claudio Solé; Mauricio Cambeiro; Jacobo Palma; Javier Aristu; Jose Luis Garcia-Sabrido; Miguel Angel Cuesta; Emilio Del Valle; Fernando Lapuente; Bernardino Miñana; Miguel Ángel Morcillo; Jose Manuel Asencio; Javier Pascau Journal: Clin Transl Oncol Date: 2022-09-28 Impact factor: 3.340
Authors: Fa Calvo; Cv Sole; R Herranz; M Lopez-Bote; J Pascau; A Santos; A Muñoz-Calero; C Ferrer; Jl Garcia-Sabrido Journal: Ecancermedicalscience Date: 2013-08-15